Trial reportDrugs & aging2016
Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate.
Trial report in Drugs & aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Pooled it
- Recommendations on deprescribing of bisphosphonates in osteoporosis guidelines: a systematic review.European geriatric medicine · 2023Pooled it
- Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.BMJ (Clinical research ed.) · 2023Pooled it
- Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.JAMA internal medicine · 2022Pooled it
- Designing and validating a clinical decision support algorithm for diabetic nephroprotection in older patients.BMJ health & care informatics · 2024Article
- Analysis of door-to-needle time for thrombolysis in acute ischaemic stroke using statistical process control charts.BMJ neurology open · 2024Article
- Age is just a number: the concept of time to benefit in older adults.European journal of hospital pharmacy : science and practice · 2023Article
- Controversies in Osteoporosis Treatment of Nursing Home Residents.Journal of the American Medical Directors Association · 2022Review
- Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.Calcified tissue international · 2022Article
- Bisphosphonate Use and Hospitalization for Hip Fractures in Women: An Observational Population-Based Study in France.International journal of environmental research and public health · 2021Observational
- Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Article
- Medication appropriateness criteria for older adults: a narrative review of criteria and supporting studies.Therapeutic advances in drug safety · 2019Review
- Limited Osteoporosis Screening Effectiveness Due to Low Treatment Rates in a National Sample of Older Men.Mayo Clinic proceedings · 2018Observational
- Clinical Management of Osteoporotic Fractures.Current osteoporosis reports · 2018Review
- Use of amniotic membrane in the treatment of patients with BRONJ: two case reports.Journal of surgical case reports · 2018Article
- Individualizing Prevention for Older Adults.Journal of the American Geriatrics Society · 2018Article
- The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis.Journal of bone metabolism · 2017Article
- Predictors and Outcomes Associated With Adherence to Weekly Alendronate in US Military Veterans: Clinical Research Study.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor physicians dealing with patients with a limited life expectancy, knowing the time to benefit (TTB) of preventive medication is essential to support treatment decisions.
objectiveThe aim of this study was to investigate the usefulness of statistical process control (SPC) for determining the TTB in relation to fracture risk with alendronate versus placebo in postmenopausal women.
methodsWe performed a post hoc analysis of the Fracture Intervention Trial (FIT), a randomized, controlled trial that investigated the effect of alendronate versus placebo on fracture risk in postmenopausal women. We used SPC, a statistical method used for monitoring processes for quality control, to determine if and when the intervention group benefited significantly more than the control group. SPC discriminated between the normal variations over time in the numbers of fractures in both groups and the variations that were attributable to alendronate. The TTB was defined as the time point from which the cumulative difference in the number of clinical fractures remained greater than the upper control limit on the SPC chart.
resultsFor the total group, the TTB was defined as 11 months. For patients aged ≥70 years, the TTB was 8 months [absolute risk reduction (ARR) = 1.4%]; for patients aged <70 years, it was 19 months (ARR = 0.7%).
conclusionSPC is a clear and understandable graphical method to determine the TTB. Its main advantage is that there is no need to define a prespecified time point, as is the case in traditional survival analyses. Prescribing alendronate to patients who are aged ≥70 years is useful because the TTB shows that they will benefit after 8 months. Investigators should report the TTB to simplify clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.